
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
LUGPA President Dr. Harris discusses legislative/policy challenges in 2020.
LUGPA President Dr. Harris discusses legislative/policy challenges in 2020. Urology Times spoke with Dr. Harris at the 2019 LUGPA annual meeting in Chicago.






